Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 125.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 120,997 shares of the company’s stock after acquiring an additional 67,276 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.12% of Intellia Therapeutics worth $1,411,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of NTLA. EverSource Wealth Advisors LLC lifted its position in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the period. Eastern Bank acquired a new position in Intellia Therapeutics during the third quarter worth about $41,000. Values First Advisors Inc. purchased a new stake in Intellia Therapeutics in the 3rd quarter valued at approximately $54,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after acquiring an additional 794 shares in the last quarter. Finally, KBC Group NV boosted its stake in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after purchasing an additional 1,020 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NTLA. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Robert W. Baird cut their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Citigroup reduced their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Barclays reduced their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Finally, Oppenheimer decreased their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $51.06.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 28,735 shares of company stock valued at $349,909 in the last 90 days. 3.20% of the stock is owned by insiders.

Intellia Therapeutics Stock Up 0.8 %

Shares of NASDAQ:NTLA opened at $9.50 on Friday. The firm has a market cap of $967.58 million, a P/E ratio of -1.75 and a beta of 1.83. Intellia Therapeutics, Inc. has a 12 month low of $9.25 and a 12 month high of $34.87. The company’s 50-day moving average price is $13.15 and its two-hundred day moving average price is $18.51.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same quarter in the prior year, the firm earned ($1.38) EPS. The firm’s quarterly revenue was down 24.1% compared to the same quarter last year. As a group, equities analysts predict that Intellia Therapeutics, Inc. will post -5.11 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.